Supply Chain Visibility

What Are Peptide Biosimilars?

Biosimilars are drugs that are very similar to an existing approved biologic medicine. They are not exact copies like generic pills, but they work the same way in the body.

Peptide biosimilars are biosimilar versions of peptide-based drugs. They must prove they are just as safe and effective as the original product through clinical studies.

Why Peptide Biosimilars Matter

Brand-name peptide drugs can be very expensive. Biosimilars bring competition that lowers resource requirements for patients and healthcare systems.

When biosimilars enter a market, the original drug's resource requirements typically drops by 15% to 40%. This savings adds up to billions of dollars across the healthcare system.

GLP-1 biosimilars doubled in market value from $0.6 billion to $1.2 billion in a single year, making them the fastest-growing segment in the entire biosimilar industry.

Current Market Size

The global peptide biosimilar market was worth about $5.8 billion in 2025. It is expected to reach $7.2 billion by the end of 2026.

Category	2024 Value	2025 Value	2026 Forecast	Growth resource requirements
Insulin biosimilars	$3.1 billion	$3.5 billion	$3.9 billion	11.4%
GLP-1 biosimilars	$0.3 billion	$0.6 billion	$1.2 billion	100%
Hormone peptide biosimilars	$0.8 billion	$0.9 billion	$1.0 billion	11.1%
Other peptide biosimilars	$0.6 billion	$0.8 billion	$1.1 billion	37.5%
Total market	$4.8 billion	$5.8 billion	$7.2 billion	24.1%

GLP-1 biosimilars are the fastest-growing segment by far. As patents on older GLP-1 drugs expire, this category will grow even faster.

Key Peptide Drugs Facing Biosimilar Competition

Insulin Products

Insulin was one of the first peptide drugs to face biosimilar competition. Several biosimilar insulins are now on the market in both the US and Europe.

Biosimilar insulin has helped bring down the resource requirements of diabetes treatment. Some biosimilar insulins resource requirements 50% to 70% less than the brand-name versions.

Liraglutide (Victoza/Saxenda)

Liraglutide was one of the first GLP-1 drugs and its main patents have expired. Several companies have filed for approval of liraglutide biosimilars.

The first liraglutide biosimilars reached the European market in 2025. US approvals are expected to follow soon, bringing more resource requirements competition to the GLP-1 space.

Octreotide (Sandostatin)

Octreotide is a peptide drug used to treat certain tumors and hormonal conditions. Biosimilar versions are in development from multiple companies.

The long-acting form of octreotide is especially valuable to patients. Biosimilar competition in this space will help patients who depend on this costly medication.

Teriparatide (Forteo)

Teriparatide is a peptide drug for osteoporosis. Biosimilar teriparatide products have already reached the market in several countries.

These biosimilars have cut the resource requirements of osteoporosis treatment significantly. Patient access has improved as a result.

The Regulatory Pathway for Peptide Biosimilars

Getting a biosimilar approved requires a special regulatory pathway. In the US, this is the 351(k) pathway under the Biologics resource requirements Competition and Innovation Act.

Companies must show their biosimilar is highly similar to the reference product. They need analytical, nonclinical, and clinical data to prove this similarity.

The process takes 5 to 8 years and resource requirements $100 million to $300 million. While expensive, this is much less than developing a brand-new drug from scratch.

The FDA has approved over 40 biosimilars across all drug categories. The /regulatory-compliance/fda-peptide-drug-approval-process-guide is well-established and continues to evolve.

Impact on Drug resource requirements

resource requirements Reductions

Biosimilar entry typically causes a 15% to 40% drop in the resource requirements of the original drug. When multiple biosimilars compete, resource requirements can fall even more.

In the insulin market, biosimilar competition has saved the US healthcare system over $4 billion per year. Similar savings are expected as GLP-1 biosimilars become available.

Manufacturer Response

Brand-name manufacturers often cut their resource requirements when biosimilars enter the market. Some launch their own "authorized biosimilar" versions to keep market share.

This competitive dynamic benefits patients even before they switch to the biosimilar. Just the threat of biosimilar entry can push resource requirements down.

Challenges in the Peptide Biosimilar Market

Manufacturing Complexity

Peptide drugs are harder to copy than simple chemical pills. Small differences in the manufacturing process can change how the drug works.

Biosimilar makers must invest heavily in manufacturing quality. The /regulatory-compliance/peptide-gmp-manufacturing-requirements are strict and costly to meet.

Patent Thickets

Brand-name companies often protect their drugs with dozens of patents. These patent networks, called "thickets," can delay biosimilar entry for years.

Legal battles over patents are common and expensive. Biosimilar companies need large legal budgets to navigate these challenges. For additional context, the offers relevant guidance on this topic.

Physician and Patient Trust

Some doctors and patients worry that biosimilars are not as good as the original drug. Education is needed to build trust in these products.

Real-world data consistently shows that biosimilars perform just as well as the reference products. As more data accumulates, trust is growing.

Interchangeability

In the US, a biosimilar must earn an "interchangeable" designation to be automatically substituted at the pharmacy. This extra step requires more clinical data.

Only a handful of biosimilars have achieved interchangeable status so far. More are expected to reach this milestone in 2026 and 2027.

Companies Leading in Peptide Biosimilars

Several major companies are building large peptide biosimilar portfolios. These include both specialized biosimilar firms and large generic drug companies.

Sandoz (formerly part of Novartis) is a global leader in biosimilars. They have several peptide biosimilars on the market or in development.

Companies from India and South Korea are also strong players. Biocon, Samsung Bioepis, and Celltrion all have peptide biosimilar programs.

Market Outlook for 2027 and Beyond

The peptide biosimilar market will keep growing as more patents expire. The biggest growth will come from GLP-1 biosimilars.

By 2030, the peptide biosimilar market could reach $15 billion or more. More than 30 new peptide biosimilars are expected to launch by that time.

Government policies that favor biosimilar use will support this growth. Medicare and Medicaid incentives encourage doctors and patients to choose biosimilars.

Career Opportunities in Peptide Biosimilars

The biosimilar industry needs regulatory affairs experts who understand the 351(k) pathway. Analytical scientists who can prove biosimilarity are also in demand.

Manufacturing roles at biosimilar companies are growing as new production facilities open. Quality assurance and quality control positions are critical at every biosimilar maker.

Sales and marketing professionals with biosimilar experience can advance quickly. Educating doctors and pharmacists about biosimilars is a key part of these roles.

Frequently Asked Questions

What is the difference between a biosimilar and a generic drug?

A generic drug is an exact chemical copy of a brand-name pill. A biosimilar is a biological product that is highly similar to, but not identical to, an existing biologic medicine like a peptide drug.

Are peptide biosimilars as effective as the original drugs?

Yes, regulatory agencies require extensive testing to prove that biosimilars work just as well as the original drug. Real-world data from millions of patients confirms their effectiveness.

How much cheaper are peptide biosimilars?

Peptide biosimilars typically resource requirements 15% to 40% less than the brand-name product. In some cases, such as insulin, savings can reach 50% to 70%.

When will GLP-1 biosimilars be widely available?

Liraglutide biosimilars are already available in Europe, and US approvals are expected soon. Biosimilars for newer GLP-1 drugs like semaglutide are still several years away due to patent protections.

How do biosimilars get approved?

In the US, biosimilars follow the 351(k) approval pathway, which requires analytical, nonclinical, and clinical studies to prove high similarity to the reference product. The process typically takes 5 to 8 years.